Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Alnylam pharmaceuticals, inc. symbols : SNY save search
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
Published: 2024-03-05 (Crawled : 16:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.17%
H: 0.0%
C: 0.0%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: -0.73%
H: 1.52%
C: 0.5%
positive blood care topline results study
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity
Published: 2024-02-15 (Crawled : 14:30) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 1.16%
H: 1.48%
C: 0.89%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.86%
H: 0.0%
C: 0.0%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: -8.62%
H: 2.18%
C: -1.71%
year pharmaceuticals financial results
Liver Disease Therapeutics Competitive Landscape and Market Forecasts to 2028
Published: 2024-02-12 (Crawled : 20:00) - prnewswire.com
ALPMY | News | $9.49 -1.11% 480K
|
Manufacturing
|
| O: 0.37%
H: 0.74%
C: 0.28%
BMY | $48.86 -0.27% 0.0% 16M
|
Health Technology
|
| O: -0.18%
H: 0.48%
C: -1.91%
ABBV | News | $167.83 -1.01% 0.0% 4M
|
Health Technology
|
| O: 0.8%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.32%
H: 0.11%
C: -1.55%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: -2.63%
H: 0.98%
C: -1.75%
liver disease therapeutics market
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
Published: 2024-02-02 (Crawled : 12:00) - globenewswire.com
TSVT | $4.28 -7.56% -8.18% 470K
|
|
| O: -1.16%
H: 9.94%
C: 2.34%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.93%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 1.4%
H: 0.28%
C: -2.68%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: -1.23%
H: 1.0%
C: 0.17%
year financial results
Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day
Published: 2023-12-13 (Crawled : 14:30) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -0.06%
H: 2.36%
C: 2.36%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.27%
H: 2.28%
C: 2.16%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: -0.14%
H: 4.22%
C: 3.97%
day innovation pipeline platform
Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH
Published: 2023-11-03 (Crawled : 11:00) - globenewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -1.79%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -3.04%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 2.37%
H: 0.12%
C: -2.54%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: 1.95%
H: 2.7%
C: 1.62%
disorders pipeline blood
Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity
Published: 2023-11-02 (Crawled : 13:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 3.0%
H: 0.0%
C: 0.0%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: 3.4%
H: 0.57%
C: -0.5%
pharmaceuticals financial results
Regeneron Reports Third Quarter 2023 Financial and Operating Results
Published: 2023-11-02 (Crawled : 11:00) - globenewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 3.0%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.08%
H: 4.96%
C: 3.4%
NTLA | $21.16 -1.72% -1.75% 860K
|
Health Technology
|
| O: 2.35%
H: 1.63%
C: 1.46%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: 3.4%
H: 0.57%
C: -0.5%
financial results
Alnylam Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine
Published: 2023-10-25 (Crawled : 23:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 0.4%
H: 1.29%
C: 1.29%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.43%
H: 0.64%
C: -0.09%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: -1.28%
H: 0.58%
C: -1.46%
publication results study
Alnylam Reports Additional Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published: 2023-10-25 (Crawled : 19:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 0.4%
H: 1.29%
C: 1.29%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.43%
H: 0.64%
C: -0.09%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: -1.28%
H: 0.58%
C: -1.46%
disease alzheimer’s positive results
Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published: 2023-10-09 (Crawled : 14:30) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: 0.0%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: -4.06%
H: 2.17%
C: -0.83%
fda drug treatment application response
Alnylam to Present Additional Data for Patisiran in Patients With the Cardiomyopathy of ATTR Amyloidosis
Published: 2023-10-06 (Crawled : 13:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.19%
H: 0.0%
C: 0.0%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: -0.16%
H: 1.44%
C: -0.84%
RNA Therapeutics Market worth $18.0 billion | MarketsandMarkets
Published: 2023-09-15 (Crawled : 15:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 1.53%
H: 0.0%
C: 0.0%
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
|
| O: 0.79%
H: 0.0%
C: 0.0%
ALPMY | News | $9.49 -1.11% 480K
|
Manufacturing
|
| O: 3.0%
H: 0.0%
C: -3.43%
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -0.26%
H: 1.04%
C: 0.03%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 1.51%
H: 0.26%
C: -0.72%
SRPT | $124.27 6.11% 5.75% 1.3M
|
Health Technology
|
| O: -0.27%
H: 0.54%
C: -0.84%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.82%
H: 0.0%
C: 0.0%
MRNA | News S | $108.82 0.86% 0.85% 3.4M
|
Health Technology
|
| O: 0.16%
H: 2.0%
C: 1.42%
IONS | $42.455 1.47% 1.45% 730K
|
Health Technology
|
| O: -0.57%
H: 0.35%
C: -1.11%
BNTX | News | $88.18 -0.35% -0.35% 280K
|
Health Technology
|
| O: 0.17%
H: 0.48%
C: -0.82%
ARWR | $23.285 -2.08% -2.13% 810K
|
Health Technology
|
| O: 0.16%
H: 0.46%
C: -5.46%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: -0.74%
H: 2.42%
C: -3.47%
therapeutics market
Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published: 2023-09-13 (Crawled : 22:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -1.8%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.99%
H: 0.0%
C: 0.0%
fda positive treatment meeting
Alnylam Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published: 2023-09-13 (Crawled : 12:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -1.8%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.99%
H: 0.0%
C: 0.0%
fda drug review treatment application
Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular Risk
Published: 2023-09-07 (Crawled : 14:30) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.03%
H: 0.0%
C: 0.0%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: -0.15%
H: 1.32%
C: -0.02%
positive treat risk topline hypertension cardiovascular results study
Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity
Published: 2023-08-03 (Crawled : 13:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -1.6%
H: 0.11%
C: 0.11%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -3.79%
H: 0.0%
C: 0.0%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: -1.35%
H: 5.58%
C: 4.38%
pharmaceuticals financial results
Alnylam Announces Partnership with Roche to Co-Develop and Co-Commercialize Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension in Patients with High Cardiovascular Risk
Published: 2023-07-24 (Crawled : 06:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.88%
H: 0.0%
C: 0.0%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: 0.06%
H: 0.0%
C: 0.0%
partnership treatment risk hypertension roche cardiovascular
Alnylam Announces Publication of Phase 1 Study Results for Zilebesiran in the New England Journal of Medicine
Published: 2023-07-19 (Crawled : 22:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.88%
H: 0.0%
C: 0.0%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: 0.74%
H: 0.28%
C: -2.21%
publication results study
Alnylam Reports Updated Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published: 2023-07-17 (Crawled : 09:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.02%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.05%
H: 1.33%
C: 0.38%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: 5.53%
H: 5.23%
C: -2.49%
disease alzheimer’s positive results
Gainers vs Losers
| 65% | 35% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 210M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.